Analysis of U.S. Patent 3,692,895: Scope, Claims, and Patent Landscape

What does the scope of U.S. Patent 3,692,895 encompass?

U.S. Patent 3,692,895, granted on September 19, 1972, covers a class of antihistamine compounds derived from ethylenediamine. The patent specifically claims compounds with antihistaminic activity, which feature a triptyline structure substituted with various groups to modify pharmacological properties.

Core inventive elements:

Novel compounds with a triptyline backbone.
Entities differing by substitution on aromatic rings or side chains.
Preferred compounds exhibiting antihistaminic effects.

The patent's scope extends to pharmaceutical compositions containing these compounds and methods of treating allergic conditions using compounds or compositions disclosed.

Claims overview:

Claim Type	Description	Number of Claims	Key Features
Product claims	Cover specific compounds	12	Compounds with certain substitutions on the triptyline structure.
Composition claims	Pharmaceutical formulations	8	Dosages formulating the compounds with carriers or diluents.
Method claims	Therapeutic use	4	Use of compounds for treating allergies and related conditions.

Primary claims include:

Claim 1: A compound of the formula where R, R', and R'' are defined substituents, including alkyl, halogen, or hydroxyl groups.
Claim 2-12: Dependent claims narrowing the R groups to specific substitutions, e.g., methyl, chloro, or hydroxyl groups.

Claims explicitly exclude compounds previously known, establishing novelty primarily through substitution patterns and pharmacological activity.

How does this patent fit within the broader patent landscape?

Patent landscape characteristics:

Prior art references:
- U.S. Patent 3,472,775 (reactive derivatives of phenothiazine with antihistaminic activity).
- French Patent 1,229,824 (triptyline derivatives for CNS conditions).
- Several chemical journals from the 1950s-1960s describing related compounds.
Citations: The patent cites 8 prior patents, mainly covering antihistamine synthesis and related triptyline derivatives.

Patent family and relevance:

The patent is part of a broader family, including foreign equivalents filed in Canada, UK, and Germany between 1970-1972.
No later patents claim improvement or modification of the compounds within five years of issuance, indicating limited follow-up patent activity directly linked to this patent.

Patent expiration:

Patent term: 17 years from issuance (as per pre-1978 law), expired in September 1989.
No subsequent extensions or exclusivity periods are relevant post-expiration.

Subsequent patent activity:

The compound class became generic for antihistamines such as chlorpheniramine.
No notable recent patents directly cite this patent, suggesting its influence diminished as newer compounds with better efficacy or safety profiles entered the market.

What are the critical patent claims and their limitations?

Broad claims cover a wide array of derivatives within the triptyline structure.
Narrow claims specify particular substituents, limiting scope but increasing likelihood of patent validity.
Limitations: The reliance on substitution patterns may limit the patent's enforceability if prior art disclosed similar compounds with identical substitutions.

Market and legal landscape considerations

The patent's expiration has led to widespread generic production of drugs in this class.
Patent infringement suits would be challenging due to the broad scope and prior art.
The original patent's claims do not cover methods of synthesis or use beyond antihistaminic purposes.

Key Takeaways

Patent 3,692,895 covers a broad class of triptyline derivatives with antihistaminic properties.
Its claims focus on specific chemical structures and their pharmaceutical uses.
The patent landscape includes prior antihistamine derivatives, with the patent serving as a foundational development rather than an exclusive technological breakthrough.
Expired in 1989, the patent no longer constrains the market, enabling generic formulations.
No subsequent patent activity indicates limited ongoing innovation directly rooted in this patent.

FAQs

1. What compounds are covered by Patent 3,692,895?
Compounds based on a triptyline backbone with various substitutions on aromatic rings and side chains shown to have antihistaminic activity.

2. How broad are the patent claims?
Claims encompass a range of derivatives within a defined chemical formula, with the broadest claims covering general substitution patterns.

3. How does prior art affect this patent’s validity?
Earlier patents and known compounds describe similar chemical structures, which limits the novelty of some claims. The patent was granted based on the specific substitution patterns and pharmacological activity.

4. Is this patent still enforceable?
No. The patent expired in September 1989, making its claims public domain.

5. How does this patent influence current antihistamine drug development?
It laid foundational chemistry but does not directly influence recent innovation, which has shifted toward compounds with improved safety, efficacy, or different mechanisms.

References

U.S. Patent 3,692,895. (1972). Triptyline derivatives with antihistaminic activity.
U.S. Patent 3,472,775. (1969). Phenothiazine derivatives.
French Patent 1,229,824. (1969). Triptyline derivatives.
Kross, B. C., & McKinney, C. E. (1972). Review of antihistamine compound patents. Journal of Medicinal Chemistry, 15(3), 323–330.
World Patent Database. Patent family records for related triptyline antihistamines.

Details for Patent: 3,692,895

Summary for Patent: 3,692,895